Hong Kong (PRWEB) November 6, 2010
Unigen Life Sciences (ULS) announces the return of Unitropin (rHGH Somatropin) a generic pharmaceutical principally used in the treatment of growth hormone deficiency, short stature, osteoporosis and wasting associated with HIV and AIDS. The decision to re-launch the discontinued Unitropin brand came amidst growing practitioner demand for a reasonably priced USP Somatropin produced in a WHO-GMP certified facility by a recognized pharmaceutical manufacturer.
Unitropin is protected by the Unigen Life Sciences internet authentication and activation system which permits patients to scratch-off a secret code on the product hologram and compare it to the serial number on the internet. The customer is able to determine if the numbers match from the factory and whether they have been activated before. Unitropin packaging has several security features reducing the vulnerability of the product to counterfeiting and protecting the patient base.
Unitropin is presented as a single 5mg multi-dose vial per box. After reconstitution, each UNITROPIN vial delivers 5mg (approx. 15 IU) of rHGH. Solvent is included.
Unitropin is offered as an Export product and will be available for fulfillment on November 10th 2010.
Qualified institutional buyers should be directed to: sales(at)unigen-lifesciences(dot)com.
Physician enquiries should be directed to: doctors(at)unigen-lifesciences(dot)com.
Unigen Life Sciences Ltd. is a licensed manufacturer of pharmaceutical products with registered offices throughout SE Asia. Unigen manages a portfolio of FDA approved pharmaceuticals which can be reviewed online in the MIMS Guide. Unigen has been operating since 2002. Void where prohibited.
Unigen Life Sciences Ltd. (HK)
Media Enquiries: media(at)unigen-lifesciences(dot)com
Regulatory Enquiries: regulatory(at)unigen-lifesciences(dot)com